Literature DB >> 34930932

MYCL promotes iPSC-like colony formation via MYC Box 0 and 2 domains.

Chiaki Akifuji1, Mio Iwasaki1, Yuka Kawahara1, Chiho Sakurai1, Yu-Shen Cheng1, Takahiko Imai1, Masato Nakagawa2.   

Abstract

Human induced pluripotent stem cells (hiPSCs) can differentiate into cells of the three germ layers and are promising cell sources for regenerative medicine therapies. However, current protocols generate hiPSCs with low efficiency, and the generated iPSCs have variable differentiation capacity among different clones. Our previous study reported that MYC proteins (c-MYC and MYCL) are essential for reprogramming and germline transmission but that MYCL can generate hiPSC colonies more efficiently than c-MYC. The molecular underpinnings for the different reprogramming efficiencies between c-MYC and MYCL, however, are unknown. In this study, we found that MYC Box 0 (MB0) and MB2, two functional domains conserved in the MYC protein family, contribute to the phenotypic differences and promote hiPSC generation in MYCL-induced reprogramming. Proteome analyses suggested that in MYCL-induced reprogramming, cell adhesion-related cytoskeletal proteins are regulated by the MB0 domain, while the MB2 domain regulates RNA processes. These findings provide a molecular explanation for why MYCL has higher reprogramming efficiency than c-MYC.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34930932      PMCID: PMC8688507          DOI: 10.1038/s41598-021-03260-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Human induced pluripotent stem cells (hiPSCs) are generated from somatic cells and can differentiate into cells of all three germ layers[1,2]. They are functionally identical to human embryonic stem cells (hESCs) but do not require the destruction of the embryo, which has made them attractive sources for regenerative medicine[3]. The original reprogramming was induced by four factors, OCT3/4, SOX2, KLF4, and c-MYC (OSKM). Since then, several new methods have been developed to improve the yield and quality of iPSCs, but the cost remains high and the production remains technically difficult[4,5]. Further complicating the application of hiPSCs is the wide variability in the differentiation capacity of different hiPSC clones[6]. We have shown that excluding c-MYC from the reprogramming factors significantly lowers the reprogramming and differentiation efficiencies of the resulting iPSCs[7]. The MYC family consists of the oncogenes c-MYC, MYCN, and MYCL in humans[8]. c-MYC was the first MYC gene discovered in human and has been a topic of cancer research ever since[9]. Tumorigenesis depends on high transformation activity derived from the N-terminus region of c-MYC protein[10]. Consequently, OSKM-based reprogramming may not be appropriate for the clinical application of iPSCs. Many groups have reported reprogramming methods that exclude c-MYC overexpression but at the cost of lower reprogramming efficiency[5,7]. MYCL is about 30 amino acids shorter in the N-terminus region than c-MYC and has lower transformation activity[10]. We found that substituting c-MYC for MYCL in reprogramming can increase the number of iPSC colonies and maintain the ability to differentiate into the cells of three germ layers[7]. Furthermore, fewer chimeric mice died by tumorigenesis after the transplantation of MYCL-iPSCs, whereas the transplantation of c-MYC-iPSCs caused lethal tumorigenesis in more than 50% of mice during two years of observation. Despite these observations, little is known about the molecular function of MYCL and the different mechanisms between c-MYC and MYCL to promote reprogramming. MYC proteins have six MYC Box (MB) domains: MB0, 1, 2, 3a, 3b, and 4 in the N-terminus and a basic helix-loop-helix leucine zipper (bHLHLZ) in the C-terminus[11], but MYCL does not have MB3a. The C-terminus of c-MYC and MYCL is essential in reprogramming due to its binding with MAX protein, allowing MYC to access the DNA[7,12]. The N-terminus is mainly known as a transactivation domain (TAD), which regulates the target gene, but its function in reprogramming is less clear[13]. We found that a mutant of c-MYC lacking the N-terminal showed low transformation activity and promoted reprogramming[7]. However, which domain on the N-terminal side is essential for reprogramming and what function it performs were not resolved. In addition, MYC proteins act as transcription factors upon interacting with several binding proteins[14]. Although MYCL-binding proteins are important for MYCL function, there are no reports about MYCL-binding proteins during reprogramming. In this study, using domain deletion mutants of MYC proteins, we found that the MB0 and MB2 domains promote iPSC-like colonies and that the MB0 domain is functionally different between c-MYC and MYCL. In c-MYC, it induced non-iPSC-like colonies by increasing nucleic proteins related to transcription, but in MYCL, the MB0 domain induced iPSC-like colonies by increasing the expression of cell adhesion-related proteins. We also found that deletion of the MB2 domain in MYC proteins prevented colony formation and that MYCL could interact with RNA-binding proteins (RBPs) via this domain. These results suggested that MYCL promotes reprogramming by regulating RNA processing.

Results

MYCL promotes reprogramming more efficiently than c-MYC

To compare the reprogramming phenotypes of MYCL and c-MYC, we used Sendai virus (SeV)-based reprogramming (CytoTune-iPS) and StemFit AK03N medium without bFGF (Fig. 1A). The SeV method has high reprogramming efficiency without genome integration, and c-MYC and MYCL SeV kits are already available[15]. The bFGF exclusion is based on the data in Supplementary Fig. S1. DMEM supplemented with 10% FBS (DMEM + 10%FBS) is the standard medium to induce reprogramming. We used DMEM + 10%FBS when introducing the reprogramming factors, but after 7 days of reprogramming, we replated the cells and used StemFit AK03N without bFGF (03N (-)) from that point on. The MOI (multiplicity of infection) of each SeV was 20. To improve the reprogramming efficiency, we compared three media combinations (Supplementary Fig. S1A). The highest number of colonies was obtained using 03N (-) during reprogramming and 03N ( +) after replating (Supplementary Fig. S1B). These results indicated that the 03N (-) reprogramming condition in the first 7 days enhances the reprogramming efficiency compared to 03N ( +). We then examined the optimal MOI of SeV for the reprogramming (Supplementary Fig. S1C). A lower MOI induced more colonies (Supplementary Fig. S1D), indicating a higher reprogramming efficiency. Following these results, we applied SeV for the transduction at an MOI of 4.3 using 03N (-) during reprogramming.
Figure 1

MYCL promotes reprogramming more efficiently than c-MYC. (A) Schematic representation of HDF reprogramming with Sendai virus (SeV). HDFs were transduced with SeV carrying KLF4-OCT3/4-SOX2 (KOS), KLF4 (K), and c-MYC or MYCL on day 0. We used an MOI (multiplicity of infection) of 4.3 for each virus. StemFit AK03N without bFGF was used during the transduction and subsequent induction of iPSC-like colonies. We performed immunostaining of the reprogramming HDFs 1 to 7 days after the transduction and analyzed the results using ArrayScan. (B) Representative immunostaining images of reprogramming HDFs stained by anti-TRA-1-60 antibody (green) and Hoechst (blue) 7 days after the transduction. Scale bar, 300 μm. Ph, phase contrast. (C) Proliferation and expression of TRA-1-60 ( +) cells during reprogramming. HDFs were transduced with SeV, including c-MYC or MYCL, and immunostaining was performed from days 1 to 7. The number of total cells was counted as Hoechst-positive cells. Mean ± SD values are shown. n = 3, *p < 0.05 by paired t-test. (D) Schematic representation of HDF reprogramming with episomal plasmid vector (EpiP). HDFs were transduced with EpiP carrying SOX2, KLF4, OCT3/4-shp53, LIN28A, EBNA1, and c-MYC or MYCL. StemFit AK03N without bFGF was used during the transfection and subsequent induction of iPSC-like colonies. We performed flow cytometry of the reprogramming HDFs every three days from 1 to 19 days plus day 21 after the transduction. (E) Representative immunostaining images of reprogramming HDFs stained by anti-TRA-1-60 antibody (green) and Hoechst (blue) 21 days after the transduction. Scale bar, 300 μm. Ph, phase contrast. (F) Proliferation and expression of TRA-1-60 ( +) cells during reprogramming were analyzed by flow cytometry. HDFs were transduced with EpiP, including c-MYC or MYCL. Flow cytometry was performed every three days from days 1 to 19 days plus day 21. Mean ± SD for n = 3, *p < 0.05 and **p < 0.01 by paired t-test. (G) The number of iPSC-like and non-iPSC-like colonies derived from 1 × 105 HDFs transduced with EpiP including c-MYC or MYCL on day 21. Mean ± SD values are shown. n = 3, **p < 0.01 by unpaired t-test. (H) Percentage of CD13 ( +) cells during EpiP reprogramming determined by flow cytometry. Mean ± SD values are shown. n = 3, *p < 0.05 and **p < 0.01 by paired t-test.

MYCL promotes reprogramming more efficiently than c-MYC. (A) Schematic representation of HDF reprogramming with Sendai virus (SeV). HDFs were transduced with SeV carrying KLF4-OCT3/4-SOX2 (KOS), KLF4 (K), and c-MYC or MYCL on day 0. We used an MOI (multiplicity of infection) of 4.3 for each virus. StemFit AK03N without bFGF was used during the transduction and subsequent induction of iPSC-like colonies. We performed immunostaining of the reprogramming HDFs 1 to 7 days after the transduction and analyzed the results using ArrayScan. (B) Representative immunostaining images of reprogramming HDFs stained by anti-TRA-1-60 antibody (green) and Hoechst (blue) 7 days after the transduction. Scale bar, 300 μm. Ph, phase contrast. (C) Proliferation and expression of TRA-1-60 ( +) cells during reprogramming. HDFs were transduced with SeV, including c-MYC or MYCL, and immunostaining was performed from days 1 to 7. The number of total cells was counted as Hoechst-positive cells. Mean ± SD values are shown. n = 3, *p < 0.05 by paired t-test. (D) Schematic representation of HDF reprogramming with episomal plasmid vector (EpiP). HDFs were transduced with EpiP carrying SOX2, KLF4, OCT3/4-shp53, LIN28A, EBNA1, and c-MYC or MYCL. StemFit AK03N without bFGF was used during the transfection and subsequent induction of iPSC-like colonies. We performed flow cytometry of the reprogramming HDFs every three days from 1 to 19 days plus day 21 after the transduction. (E) Representative immunostaining images of reprogramming HDFs stained by anti-TRA-1-60 antibody (green) and Hoechst (blue) 21 days after the transduction. Scale bar, 300 μm. Ph, phase contrast. (F) Proliferation and expression of TRA-1-60 ( +) cells during reprogramming were analyzed by flow cytometry. HDFs were transduced with EpiP, including c-MYC or MYCL. Flow cytometry was performed every three days from days 1 to 19 days plus day 21. Mean ± SD for n = 3, *p < 0.05 and **p < 0.01 by paired t-test. (G) The number of iPSC-like and non-iPSC-like colonies derived from 1 × 105 HDFs transduced with EpiP including c-MYC or MYCL on day 21. Mean ± SD values are shown. n = 3, **p < 0.01 by unpaired t-test. (H) Percentage of CD13 ( +) cells during EpiP reprogramming determined by flow cytometry. Mean ± SD values are shown. n = 3, *p < 0.05 and **p < 0.01 by paired t-test. Next, we conducted immunostaining to analyze the expression of TRA-1-60 from days 1 to 7 after the transduction (Fig. 1A). TRA-1-60 is a glycoprotein and major cell surface marker of hiPSCs and hESCs[16]. We quantified the results using a high-content imaging system, ArrayScan, because the cell number was small during SeV reprogramming for the first seven days, making flow cytometry challenging. On day 7, we observed that c-MYC and MYCL induced a small cell mass to form colonies, but only the colonies induced by MYCL expressed TRA-1-60, while those induced by c-MYC looked like cell aggregations (Fig. 1B and Supplementary Fig. S2). Cell proliferation was highly increased in human dermal fibroblasts (HDFs) transduced with c-MYC compared to MYCL. On the other hand, the percentage of TRA-1-60 ( +) cells increased more in MYCL-transduced HDFs on day 3 after the transduction (Fig. 1C). This difference may be because c-MYC has higher transformation activity than MYCL, which causes different phenotypes, especially cell proliferation[10]. We confirmed these reprogramming phenotypes using episomal plasmid vector (EpiP)[17] (Fig. 1D). SeV systems have a higher gene transfer efficiency, leading to more efficient reprogramming. However, we could modify the reprogramming vectors, which is useful for evaluating the molecular mechanism of c-MYC and MYCL, only when using the EpiP system. Similar to the results with the SeV method, few colonies expressed TRA-1-60 in c-MYC-transfected HDFs (Fig. 1E and Supplementary Fig. S3A). However, the transfection of MYCL resulted in a higher percentage of TRA-1-60 ( +) cells and lower cell proliferation than the transfection of c-MYC (Fig. 1F and Supplementary Fig. S3B). These differences between MYCL and c-MYC were more obvious with EpiP reprogramming than SeV reprogramming (Fig. 1C, F), probably because of differences in the gene transfer efficiency[15,17], the expression of the transfected factors, cell toxicity, and the time required for the iPSC-like colonies to appear: the SeV system requires about 7 days, but the EpiP system needs about 21 days based on our observations. We found two types of colonies: “iPSC-like” and “non-iPSC-like” colonies. The iPSC-like colonies produced by MYCL were more flattened and showed a monolayered colony morphology, with each cell tightly packed and expressing TRA-1-60. The non-iPSC-like colonies produced by c-MYC showed a cell aggregation-like morphology, in which individual cells were irregularly aggregated and did not express TRA-1-60. We counted the number of iPSC-like and non-iPSC-like colonies on day 21 and found that c-MYC induced iPSC-like colonies as well as many non-iPSC-like colonies, but MYCL induced almost only iPSC-like colonies and more of them than c-MYC (Fig. 1G and Supplementary Fig. S3). It has been reported that before the increase in the expression of TRA-1-60, a decrease in the expression of CD13, a marker of fibroblasts[18], is observed in somatic cell reprogramming. Therefore, we confirmed the expression of CD13 during reprogramming. The percentage of CD13 ( +) cells decreased daily in HDFs transduced with c-MYC or MYCL, but the number of CD13 (-) cells rapidly increased in c-MYC compared to MYCL (Fig. 1H and Supplementary Fig. S4). In particular, the CD13 (-) TRA-1-60 (-) population was larger on day 10 with c-MYC reprogramming than MYCL reprogramming, but the CD13 (-) TRA-1-60 ( +) population from days 16 to 21 was larger with MYCL reprogramming (Supplementary Fig. S4). These results suggested that MYCL promotes TRA-1-60 ( +) cells more than c-MYC, but c-MYC suppresses CD13 expression more than MYCL.

MYC Box 0 and 2 domains are crucial for colony formation during reprogramming

Next, we prepared domain deletion mutants to identify which domains in the N-terminus of MYC proteins influence reprogramming (Fig. 2A and Supplementary Fig. S5). We previously showed that a c-MYC mutant lacking transformation activity enhances the formation of iPSC-like colonies. This mutant has a point mutation in the transactivation domain of the N-terminal region, W135E (Fig. 2A and Supplementary Fig. S5B), but can bind to genomic DNA[7]. On the other hand, the bHLHLZ domain in the C-terminus region is a well-known binding domain of MAX[19]. Mutants in the C-terminus region prevent MYC proteins from binding to DNA and thus reprogramming[7]. Finally, we tested the reprogramming activities of these mutants using the EpiP reprogramming system because, as explained above, this method provided a clearer phenotype and was easier to manipulate than the SeV method.
Figure 2

MYC Box 0 and 2 domains are crucial for colony formation during reprogramming. (A) Schematic representation of WT c-MYC and MYCL protein. Black boxes show important domains for MYC function, including MB0, 1, 2, 3a (c-MYC only), 3b, 4, and basic-helix-loop-helix leucine zipper motif (bHLHLZ). The percentage of common amino acids in each MYC box domain between MYCL and c-MYC is shown (Identity%). The numbers on the right indicate amino acid lengths. (B) Number of iPSC-like and non-iPSC-like colonies transduced with EpiP including c-MYC-WT/mutants (left) or MYCL-WT/mutants (right) on day 21. Mean ± SD values are shown. n = 3, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by ordinary one-way ANOVA and Dunnett’s test vs. WT. (C) Expression of TRA-1-60 ( +) HDFs and CD13 ( +) HDFs transduced with EpiP including c-MYC-WT/mutants (left) or MYCL-WT/mutants (right) on day 16. Mean ± SD values are shown. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by ordinary one-way ANOVA and Dunnett’s test vs. WT. (D) Representative flow cytometry images for TRA-1-60 and CD13 for HDFs transduced with EpiP including c-MYC-WT/ΔMB0 or MYCL-WT/ΔMB0 10 and 21 days after the transduction. Numbers indicate the expression percentage of each quadrant. (E) Proliferation of HDFs transduced with EpiP including c-MYC-WT/ΔMB0 or MYCL-WT/ΔMB0 10 and 21 days later. Mean ± SD values are shown. n = 3, ***p < 0.001 by ordinary one-way ANOVA and Dunnett’s test vs. c-MYC-WT. The number of cells was counted using a Cell Counter model R1 (OLYMPUS).

MYC Box 0 and 2 domains are crucial for colony formation during reprogramming. (A) Schematic representation of WT c-MYC and MYCL protein. Black boxes show important domains for MYC function, including MB0, 1, 2, 3a (c-MYC only), 3b, 4, and basic-helix-loop-helix leucine zipper motif (bHLHLZ). The percentage of common amino acids in each MYC box domain between MYCL and c-MYC is shown (Identity%). The numbers on the right indicate amino acid lengths. (B) Number of iPSC-like and non-iPSC-like colonies transduced with EpiP including c-MYC-WT/mutants (left) or MYCL-WT/mutants (right) on day 21. Mean ± SD values are shown. n = 3, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by ordinary one-way ANOVA and Dunnett’s test vs. WT. (C) Expression of TRA-1-60 ( +) HDFs and CD13 ( +) HDFs transduced with EpiP including c-MYC-WT/mutants (left) or MYCL-WT/mutants (right) on day 16. Mean ± SD values are shown. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 by ordinary one-way ANOVA and Dunnett’s test vs. WT. (D) Representative flow cytometry images for TRA-1-60 and CD13 for HDFs transduced with EpiP including c-MYC-WT/ΔMB0 or MYCL-WT/ΔMB0 10 and 21 days after the transduction. Numbers indicate the expression percentage of each quadrant. (E) Proliferation of HDFs transduced with EpiP including c-MYC-WT/ΔMB0 or MYCL-WT/ΔMB0 10 and 21 days later. Mean ± SD values are shown. n = 3, ***p < 0.001 by ordinary one-way ANOVA and Dunnett’s test vs. c-MYC-WT. The number of cells was counted using a Cell Counter model R1 (OLYMPUS). The EpiP mutants were transfected into HDFs with other reprogramming factors, and the number of iPSC-like and non-iPSC-like colonies was counted (Fig. 2B and Supplementary Fig. S6). c-MYC-ΔMB0 promoted the formation of iPSC-like colonies and inhibited the formation of non-iPSC-like colonies compared to c-MYC-WT. In contrast, MYCL-ΔMB0 showed almost no ability to form iPSC-like colonies (Fig. 2B). We confirmed that the protein expression of each domain deletion mutant by western blotting showed no difference compared with c-MYC- or MYCL-WT (Supplementary Fig. S7 and S8). These results demonstrate that the MB0 domain has different functions in c-MYC and MYCL for reprogramming and that c-MYC-ΔMB0 has a similar function as MYCL-WT. Figure 2B shows that c-MYC-ΔMB1 promoted iPSC-like colony formation like c-MYC-ΔMB0, but it also led to the formation of non-iPSC-like colonies. The formation of iPSC-like colonies by MYCL-ΔMB1 was about a quarter that by MYCL-WT. Unlike c-MYC-WT, c-MYC-ΔMB2 did not induce non-iPSC-like colonies, but it did induce a rate of iPSC-like colonies similar to c-MYC-WT. MYCL-ΔMB2 showed little ability to form iPSC-like colonies, resembling MYCL-ΔMB0. c-MYC-ΔMB3a, -ΔMB3b, and -ΔMB4 had similar colony-forming activities as c-MYC-WT. MYCL-ΔMB3b showed the same reprogramming efficiency as MYCL-WT, but MYCL-ΔMB4 formed about the same small number of iPSC-like colonies as MYCL-ΔMB1. The ΔbHLHLZ mutants of both c-MYC and MYCL failed to induce colonies and were therefore considered to have lost MYC function completely. Thus, the results indicate that in c-MYC, the MB0 and MB2 domains are repressive for iPSC-like colony formation, but in MYCL, they are promotive. Other domains also influenced the colony formation efficiency, but the effect was small. Next, we analyzed the effect of the MYC-deletion mutants on the expression of TRA-1-60 and CD13 by flow cytometry 16 days after the start of reprogramming (Fig. 2C). Mutants that increased the number of iPSC-like colonies also increased the expression of TRA-1-60, while those that reduced the number of iPSC-like colonies lowered the TRA-1-60 expression (Fig. 2C and Supplementary Fig. S9). c-MYC-WT showed little TRA-1-60 expression, whereas c-MYC-ΔMB0 upregulated the expression. MYCL-ΔMB0, unlike MYCL-WT, failed to upregulate the expression of TRA-1-60. The CD13 expression was also correlated with colony formation. In c-MYC, a significant decrease in CD13 expression was observed for mutants that promoted non-iPSC-like colony formation. As for MYCL, only a slight decrease in CD13 expression was observed for mutants that promoted iPSC-like colony formation. From these results, we concluded that the MB0 domain is essential for the function of MYC in reprogramming but functions differently between c-MYC and MYCL. To analyze the function of the MB0 domain in more detail, we analyzed the expression of TRA-1-60 and CD13 10 and 21 days after the start of reprogramming by flow cytometry (Fig. 2D). In the case of c-MYC-WT, there was a strong decrease in CD13 expression on day 10, and most cells were CD13 negative on day 21. In the cases of c-MYC-ΔMB0 and MYCL-WT, there was a slight decrease in CD13 expression on day 10, and more than half of cells were expressing TRA-1-60 on day 21. Finally, in the case of MYCL-ΔMB0, there was no change in CD13 or TRA-1-60 expression. More study is needed to determine how CD13 is regulated by c-MYC and MYCL. Additionally, c-MYC-WT showed higher cell proliferation on day 10, but c-MYC-ΔMB0 resulted in a lower cell proliferation comparable more with MYCL-WT than with c-MYC-WT on day 10 (Fig. 2E). We attributed this effect to the lost transformation activity of c-MYC-ΔMB0. From days 10 to 21, the cell proliferation increased significantly in c-MYC-ΔMB0 and MYCL-WT, and a concomitant increase in the CD13 (-) TRA-1-60 ( +) population was observed (Fig. 2D, E). These observations suggest that the number of cells that were reprogrammed increased rapidly with c-MYC-ΔMB0 and MYCL-WT. With c-MYC-WT, the cell proliferation continued until day 21. However, the CD13 (-) TRA-1-60 ( +) population hardly increased (Fig. 2D), indicating that these cells were not reprogramming but changing to other highly proliferative cell types. From these results, we concluded that the MB0 domain functions negatively in c-MYC and positively in MYCL for reprogramming.

MYCL regulates cytoskeleton- and cell adhesion-related proteins during reprogramming via the MB0 domain

To confirm which genes are regulated by the MYCL MB0 domain in reprogramming, we analyzed protein expressions during reprogramming because it was reported that gene expressions do not correlate well with protein expressions[20]. We performed a comprehensive analysis of expressed proteins during reprogramming induced by c-MYC and MYCL WT and ΔMB0 mutants. We used SeV-reprogramming HDFs on days 3, 5, and 7 days and EpiP-reprogramming HDFs on day 10 as samples for mass spectrometry (MS) (Fig. 3A) because the percentage of TRA-1-60 ( +) cells was much higher with SeV than with EpiP for observations up to day 7 (Fig. 1C, F). There was more than a two-fold increase in the expression of 520 (SeV) and 128 (EpiP) proteins with MYCL-WT reprogramming compared to c-MYC-WT reprogramming (Fig. 3B, groups (i) and (ii), respectively) and 183 (EpiP) proteins with c-MYC-ΔMB0 reprogramming compared to c-MYC-WT reprogramming (Fig. 3B, group (iii)). Overall, we identified 18 proteins common to the three groups (Fig. 3B, group (iv)). Then, we applied a Gene Ontology (GO) analysis using DAVID and detected enriched terms during reprogramming[21,22] (Fig. 3C, D, and Table 1), finding cytoskeleton- and cell adhesion-related proteins are involved in the promotion of reprogramming by MYCL-WT. The same analysis was performed to identify proteins whose expression was upregulated by c-MYC-WT compared with MYCL-WT and c-MYC-ΔMB0 (Supplementary Fig. S10A and Table 2). These proteins were associated with the proliferation of non-iPSC-like colonies. We found that c-MYC-WT regulates proteins involved in cell proliferation, such as the cell cycle and DNA replication. To understand the function of the MB0 domain in reprogramming, MS analysis was applied to HDF samples transfected with MYCL-WT, MYCL-ΔMB0, or c-MYC-ΔMB0 (Supplementary Fig. S10B and Table 3). GO analysis indicated that these proteins were associated with cell adhesion and RNA processing.
Figure 3

MYCL regulates cytoskeleton- and cell adhesion-related proteins during reprogramming via the MB0 domain. (A) Schematic of the mass spectrometry (MS) and GO analysis (DAVID). (B) Venn diagram of upregulated proteins during iPSC-like colony formation. (C) Molecular functions from the GO analysis of the four groups in (B). (D) KEGG pathways from the GO analysis of the four groups in (B).

Table 1

MS analysis of identified proteins in cells reprogrammed by MYCL- or c-MYC-ΔMB0.

(i) Proteins enriched more than two-fold in MYCL-WT compared with c-MYC-WT (SeV)
NRP1PMELIQCHZNF507C1QTNF3GLIPR2
ING1THOC7RPAINDGCR8KRASPIPOX
CCNL2ACOT8KCNMA1TTC38MRI1DLGAP5
CHPF2P4HA1HMCN1STRA13SMG5FAM83D
MTFR1LTSPYL1CROTPLPP1PRKACBFSD1
REPIN1MKLN1CPS1MDP1ZWILCHST6GAL1
MCL1SRRFAM134AUSP34CEP41MATN2
AQP1PPLSONARL14EPACSS3KLHL11
FAIMMCMBPCOL1A1MOCS3SHC1DPT
VCPIP1TPM2CLDN7C18orf32SAGPOSTN
AKAP11AMDHD2AHCYL2MASTLMAP3K2COPZ2
ARFGEF3HBA1,HBA2S100PCCNYL1RALGAPBACTR1B
PIAS4PFKFB3FAM134CSDSLPPICNR3C1
FYNSPASTMAP4K2COQ3CENPVHERC2
CDS2TADA2BXPCMX1PCSK9SDPR
CEP131FEM1AACTG1TNCITPR3GNPTG
SH3BGRL2QSOX1LSM4FBXL18SH3BP5LFARP2
ZIC5PASKFLYWCH2TMEM119FAPAGTPBP1
ANKIB1EDEM3PANX1CCDC28ADDX58FOXK2
ERICH1KIAA1211ZMYM4FN1ARSACSNK1E
MTRRNCOA3PATZ1UBE2SDDB2CCDC68
POLG2C10orf76ADIRFCALD1RALGAPA1NUDT9
YAE1D1C14orf142TSPAN14PTGISFAM208APANK1
TCN2TAGLNALG8THAP11NFICTMEM165
BLOC1S6FAM21ANCOR2COL12A1TGFBICRELD1
MARH5CNOT8RANGRFMED16CDAGULP1
WDR54METNOA1PRKG1CHMP1ASHARPIN
RRP8TBC1D7CPQIFIT1THBS1HSDL2
GORABTRAF6AHDC1DDX60NDUFB6ARHGEF6
CERCAMNPEPL1GPR107MAP3K15MRS2ELP3
TPM1COMMD8MED4HACL1IGFBP3HTRA1
CD99L2PEX16GINS4DSCR3UBE2G1EIF4EBP1
DYNC1I2ACTN1YPEL5SMG6ITGB4PTGES
TPK1REEP6PMF1PTBP2IFIT2PUM1
DYNC2H1KDELR3VIPAS39KIF1BEMILIN2CRIP2
HIGD2AC7orf26DNM2MMP2KANK2DHX30
RAP1BDNAJB5MRPL33SPANXA2-OT1PIRSDCBP
HMGXB4POLGFOXK1PEX1LGALS8LAMC1
DNAH6PDIA4MTMR14S100A14CNTLNSLC25A32
TMED4SPARCGBP1CNN2GCC1CTHRC1
STAU2SUPV3L1DNAJC16KIAA0430CASP4NID2
FAM69CTIMP2OGFOD3EEDDCXPRNP
KCTD15GSPT2PCNTSTARD4OTUD7BPPP3CC
WDR35CTSZSLC15A4BASP1SLC44A1AKR1C2
COA3RAB2BGNA12OPA3INPP5AGAP43
CAAP1VWA8PALMKRT17MIEF2IKBKB
C1orf198BUB1ZBTB7ACD248ACOX1DNAJA4
CNN1ANAPC4LOXLAMA5COL2A1KRT6A
LRRC41COL6A3CABIN1ECM1MED8KIF21A
NOL8SLC30A5COL16A1TWISTNBGREM1ICAM1
OSBPL11TBC1D15HORMAD2EPHA2MRPL51B3GALT6
USP9YVKORC1ETNK1MACF1STAG3SH3KBP1
BCAR1KHDRBS3TLE3IGF2STARD3NLCTDSPL2
FIBPRANBP10IFT74SERPINB2SAMD9FZD7
LGALS1CSRP1FBLN1SERPINF1SHCBP1TUBG1
CAPN5PTK7PLAURZNF185SGF29RASA3
ACSF3DNA2PRSS23PKP3GDAP1CAV2
FBXO2CCND1SLC34A3KYNURBM23ACBD7
MAP2MIC13IFI44PIK3CAKLC4ODR4
GATCTANGO6MITD1ATL1ANAPC13SP100
MYL9COL6A2PPIL2MPDZCCBL1TGM2
TGS1CDYLKRT10SNX32OGNFMNL3
LAMB1CSRP2MON2FAM127AWDR4KRT14
BEND3TRIM21RPS6KA4LENG8SPRR3FRG1
KLK14CDC34ASAP2TAP2NEXNINPP5B
TPM4PPFIA1KRT16LIMK1HOOK2PPP2R2D
CPLX1SUN1WDR73WWC3SMG7COL1A2
CCDC92MYCLDESI2FYCO1RAC2SEMA7A
TIMP3PKD1L3COL5A1PYURFDPYSL4SNX24
SERPINB8FBXO3RNF31AKTIPBAZ2AUGGT2
HSPB1CBX2IFIT3QPCTLC1orf50CAV1
CD58COL11A2ISG15RPL26L1TYW3CD44
PARP2GOLT1BFOSL1GRB7CREG1HOMER3
HSPB6ABRNID1ECT2RAP2ANDRG1
COL5A2AURKAGSDMDENGWDR55WNT5A
MRGBPEP300MAU2CHST14GHDCNPHP3
FABP3ANPEPARHGDIBBST1NABP2SIRT5
DTX3LHAUS7LTBP2CLINT1PXMP4DPY19L1
ARL5ARNF113ACRBNGGA1UBE2FGPNMB
NT5ECILPMROH2BSEPT5ILF3TANC1
STX3NOTCH3PLCG2ARFIP1NCOA5QSOX2
SLC2A1S100A6CDCA5CALHM2KDM4BTIMELESS
F13A1COMMD9RENMECP2TNXBZYG11B
AHNAK2RDH10CLIC3MMESLC39A14GGCX
S100A4ZCCHC6CD9CD82LTBP1STK11
UAP1L1MED12PXNGOSR2B3GNT5ABI3BP
ITGA2OASLCTSKVAMP8

Four groups are described: (i) proteins whose peptide counts increased more than two-fold in MYCL-WT/HDFs compared with c-MYC-WT/HDFs using SeV on day 3, 5, or 7; (ii) proteins whose peptide counts increased more than two-fold in MYCL-WT compared with c-MYC-WT using EpiP; (iii) proteins whose peptide counts increased more than two-fold in c-MYC-ΔMB0 compared with c-MYC-WT using EpiP; and (iv) commonly identified proteins. Bold fonts in the group (ii) indicate identified proteins with p < 0.05 (two-sample paired t-test). n = 3 for EpiP reprogramming.

Table 2

MS analysis of identified proteins in cells reprogrammed with c-MYC.

(i) Proteins enriched more than two-fold in c-MYC-WT compared with MYCL-WT (SeV)
ATXN7L3BTIMM21SLC2A3CA14CRLF3SYT6
TMEM161AMTM1METTL15NKAPCDS2MRS2
MARS2ERCC2TDP1MFAP4ANAPC16CARS2
NOLC1IGHMBP2MRPL34FECHPARP2ING1
ADNP2STEAP3AK6PDZD8EPB41L5PEX16
ZER1CKS1BGGPS1DBNDD1MIEF1FUCA1
ADSSL1POTEJTMEM209CCNL2TOP3AULK1
MGAFAM162AAMMECR1ISG20L2CEP78NOM1
PAPD4PROCRIFRD2LRRC41UBR3PHF3
RIN1SPPL2BARAFDNM2HPS5PSEN1
PARD3ARHGEF16RHPN2PRPF18SEMA4CRPUSD3
NYNRINARHGEF7VRTNPHF10DMDRPL26L1
RANBP6CNOT4TSPYL5CDC25CREEP4FADD
INPP5FZBTB7AGPN3RBPMS2BRAFORC6
CACNA2D2AP1B1NCAPD3RRP8MASTLPOLR2M
CASC3NCLC1orf174LRRC14SLC27A3ACSF3
DHRS11RBM23WDR55CAMK4NDRG3ALS2
NOVA1SOX3CLCN7EHMT1C7orf26NSUN5
NMRAL1STK25NFKB2OSBPL1AVPS37BRAD23A
HS2ST1LYARPHKA1SDC4MGST2SNTB1
MEN1WDR4DDX28C1orf198AKAP9COQ9
STYXPHF5APCDH1TMSB4XAP1G2MYO1G
UCKL1APCTBC1D15FASTKD1APCDD1LMARH5
ULK3LONP2SETD1AETFDHANKS1ALRP8
PALD1ANAPC5CARMIL1GATMPANX1NME3
UBA52ZNF806NCOR2DVL2CTDP1PHKB
GINS3DNPH1CDCA5BCKDKTTF1TGFBRAP1
HAUS2HMGCRSNCAKLHDC4TBPAP1M2
E2F4AFAP1L1ZMYM6NBN4BP2TRIT1CCDC134
ATL1INTS6CHD8SPINT2RASA2NCK2
MAL2ATAD3ASLC25A32LSAMPACOT8KIFAP3
JARID2CLSTN1USP36PTGISPIAS4TMEM41B
SEC14L1TUBGCP4GEMIN8VWA9RPP25LNRBP2
DOLPP1WARS2PLEKHA6MRGBPZCCHC6ZFP36L1
SLC4A7SCARB1ARID1BPMF1XXYLT1ANKRD50
MT-CO1METRBM47LIN28BEXD2GORAB
GCSHPLTPPRKAB1CUTCSDSLFARS2
LRRC8EARHGAP12FBXW9PMS2NAA30STRA13
FASTKD5ZCCHC10TTKBNC2COX16BCS1L
NDE1STX3LARP1BPTCD1TPD52SMG1
ACBD7TRIP12PTPMT1ASB3MTG1ANKRD12
STK33HEXIM1RBM45ATG9AANKIB1B3GALNT2
C12orf43SLC25A15NDUFAF5BAG4NOA1SFRP2
VPRBPFOXK1GPM6BPOLETRADDAMFR
RPS6KA1PLA2G4ASELOPROM1CHTF18BOD1
SPC24KAT7RAB17IGFBP6PNPLA4AGTRAP
UBE2Q1HIGD2ARAPH1SDF2ARHGAP4ODR4
MRPS18CQSOX1COX17CHUKRAPGEF2GINS1
DFFACENPVPTPN9FUT11ERMP1SOGA1
DHX32GEMIN6HDHD2GLE1PTPRZ1CREG1
GATCPDXPMID1WRAP53POU2F1CA2
APPL1TMEM14CTXNIPSLC7A3FABP6ITGA2
CWC22MPDZPIGGACTBINCENPCARNMT1
RHBDD2MRPL38PUM1HPDLNME4CDKN2A
TRIM27ARHGEF10LBDH1CDC26CTU1ATF7
HMGXB4L3MBTL3MAP1LC3AISLRURB1MRPL21
CAMK1RILPL1WDR37IGF2BP1NAPEPLDDPH6
FCF1ANKRD29ANAPC13CD3EAPWDR89SLC25A17
DNA2CENPMCEP170BGCACSTF2TNKRF
SLC35A2PMS1SLC5A6COQ5SPRRBM15B
USP19LAMA4DNM1LINTS2BCAS3KIF22
NHEJ1RPP40TNCSPNS1RPRD1ADDB2
IFIT5ARMCX1FAT1DAPBMPR1ANPHP3
ARID3AMRPL13ZBED1GTF2H1PATZ1DPH2
C11orf98RRP7AAKAP1ANAPC1NUDT16CD74
DCAKDASB6DNMBPUTP11LTUBG1HAUS7
GAAPDK1DOHHISYNA1BRMS1EXOC6
ARAP3CHKBNOL8DDX52ORC5COA7
NAA40IQSEC1TRIM24DNTTIP1HEATR6SH3BP4
ZMYM3MED30CLASP2PRPF38BTMEM256GTF3C2
MRPL10NDUFAF7VCPIP1HSPB11CASP7TOR1B
ITPR2PRPF39GCFC2KIF21ADPPA4TIMM8B
GTF2H4MRPL16BAZ1AEXOC6BMRPL41POLR3B
USP9YSYNE2MID1IP1MOCS2METTL5PRUNE
UBE2V2CDH1GJA1CHMP6RCC1RAPGEF6
COMMD9HMBSSQLEIGFBP2DIAPH2EPB41
HIST1H1EMAP3K4CDK18ARL15UQCC1HTATIP2
PTDSS2TATDN2MTA1SNX18EIF1BMAEA
SCAF1UBE2J2NUP37BAG1TSSC4RCOR2
FAM213AMFFTTLL12UBXN6EFEMP2ZZEF1
NFYBPDS5BFXNAGPAT5ARFGEF2TCOF1
SCAF11RAPGEF1PARGPRIM1USF1L1TD1
SEPHS1BRD8POP7EXT2TSEN34CAMKV
SLC29A1MBD3PPIFMTX3COG1FASTKD2
ARL14EPMRPL40CD320MBD1VARS2BRD3
MRPS18BACY1PPIERIF1VPS8POGZ
RSL1D1PAK1STRBPTERF2TOP2ASLC39A10
QRICH1CISD1POLBDHX37TRMT5TIMMDC1
TRABDSONSETLYSTRNASEH2BMVK
ZC3HC1NDUFC1HSPA4LEXOSC1TCEANC2NASP
CYP2S1NSMCE3HPRT1HUS1PRRC2ARDH13
KANK1PHF14RBM7SIRT5QPCTLCROCC
LIMK2CWF19L1KIF1BVPS39CHD7YPEL5
SLC7A5VPS25LRWD1FPGSNT5C3ANCKIPSD
PSIP1CELF2MDC1ANP32AACADSBGPC4
TUBB4ABOP1NT5CCTSCANKLE2ORC4
UTP18CHST14NUS1PLK1GPKOWSIKE1
ADAM15NUDCD2SSU72NFYCLIG1MSH2
HNRNPRMSI2STK26EBPITPK1STAU2
URI1SLC7A8MANBALRNGTTPRIM2SEC24B
MRPS34RMND5AF11RSCAF8RPAP1SPATA5L1
RCC2POLRMTSERF2TMEM115PARP1C2CD5
BEND3BRAT1TERF2IPMT-ND2FAM136ANOP2
ARL5BGFM2WDR3AARSD1PPIDHRSP12
CHD2MRPL45YTHDF1THEMISINTS4PLEKHA1
CBX3SIRT7CENPFCAMSAP2MCCPTPN2
NANOGSLBPMCATMRPL24MZT1ANAPC4
HIST1H1AKPNA2MED14NDUFB9NEFLDUS3L
HSP90AA4PCMSS1ZNF706PTRHD1PBRM1ABI3BP
MED10PFASBRIX1QRSL1THNSL1ADRM1
CECR2NCOA5ABRACLWIPF2USP28GEMIN4
CHD1SBNO1LSM12COG2TARS2KIF11
CHD1LMLH1MNAT1DDX47SRPK1NACAP1
XPCNELFCDMPP6HAUS6TANC1PPAN
MRPL33PUM2MRPL15FAM65AERI3TOM1L2
TIMM13SPRYD4MICU1HMGN5XPO4WDR43
DDX20YTHDC2SLC25A22CACUL1PCF11PRC1
DNAAF2ACAT1RWDD4DHPSPFKMNUDT16L1
MTMR2GPN1SMARCA4EI24SCFD2PPP3CB
RNASEH2AGTF2E2SMARCD1ADCK3TRMT1RABEP1
CD97GLT8D1UBR5HLTFTXNRD2TDP2
CCNYNCAPD2USP48LRCH2UBQLN1TRIP10
MCM3HSPA14ZBTB8OSMAP2K7APOBEC3CTTC27
DYSFMINABAK1HERC2POLG2TRAP1
EXOSC7RCL1C17orf62PUS7CASP6ISOC1
THYN1MYL6CBR4RFC3SRSF10LCLAT1
HIBADHUHRF1DHX57MCM6UBL4AMRPS17
TFRCGALK2MKI67CEBPZCHRAC1TTC4
METTL3GSTZ1UBE2OLRSAM1NSA2AGPAT4
MRPS5MAP3K7ZNF330MLLT11HK2BLMH
PCCALYPLAL1CPSF2PEX3INPP4ASORD
SLC35F2MRPL23GNL3WBP11SAP30INPPL1
TBC1D9BMRPS31GMPSIMPDH2SSRP1LBR
TRIM28NELFBLDAHDDX21TWSG1RBMX
NDUFAF1PHF6TFB2MEBNA1BP2ZMYM2MLYCD
URODPKP3NUBP2FANCIARIH2ZNF22
USP11ARFRP1PKN1FAR1MYBBP1APDS5A
CHMP7COASYSAP18GTF3C4SMARCAD1DNAAF5
CTAGE5GARTUBE2IMRPL27ENY2PDK3
RUVBL1PEAK1WDR6MYEF2PWP2RPA2
EXOSC4FRA10AC1ADAD2NARS2FAM64AXRCC4
GTF2E1DDX51BMS1OGFRMRPL3CHAC2
PES1IGF2BP3LDHBORC3MSH6DPYSL5
HEATR1KATNA1PTMASLC52A2NLE1MCM7
POLD1MCM2CXorf56SMAD5GPATCH4STOML2
FLVCR1MYH14DAXXZCCHC8TAMM41TOMM34
LGALS3BPPARNKIF1BPC5orf22TP53RKNACC1
MRPS30TKTELAC2PRKCIPDCD11DNAJB4
MTMR12SUPV3L1DARS2RAVER1SIGMAR1DHODH
SLC3A2BTAF1HSDL1EIF3CTBPL1NOC2L
MRPS28CADM1MRPL37SRIBZW2NDUFC2
PCCBDNTTIP2PCBD2TRIM2CPSF1RABGGTB
RFC5ECT2AGTPBP1TRIM22ECM29PANK4
C11orf73MCAMTHUMPD1WDR18RNPS1SCO1
TIMM17BINTS8TUSC3DCAF16GTF2A1SIRT1
UTP6MRPL11XRN1DCTPP1HSPBP1TUFM
WDR92PIRACAA2DNAJC2NPM3ADNP
CERS6NUDT12APTXDSG2NTHL1BOLA3
DDX24NUP35ATL2NOL11DDX31ATPAF1
GCDHRCHY1C12orf10HIP1RPRPS2MCM5
WDR75RHOT1KIAA1211DDX54RSPRY1CDC123
NOP16TACO1GLMNHOOK1WNK1NUP155
POLR1ATBL3GNAI1KIAA2013C7orf50GUSB
GUF1TIMM17AGRWD1LBHCCNKILKAP
SMYD5AGLPORLIG3CMTR1LRBA
WDR5TOMM5ARL8APCK2PDCD4NAT10
ACO1TSC2GNL3LMTFP1ABT1KEAP1
ANKRD28UBTFSTK3SCAPPPATPSAT1
APOA1BPWDR54SYT1SCRIBPTBP3RNASEH2C
APOOASF1AGSPT2SDHBSUPT16HDBR1
PSME3PPWD1UBQLN4CHAF1ATRMT10CSACS
BYSLCDH13USP24ARID1AGJB2TEX10
UBA2CLUHARL2AS3MTABCC1MRPL57
DDX56EIF2DATP1B3DCAF8AGKAIF1L
RBM42FEN1CCDC12ELOVL6EFNB1NCAPG2
SARS2OSBPL2CDCA8GNA13ATF7IPCCDC50
ADI1HAUS8C1orf131GOLM1DEKDTD1
MCL1INTS1AHCYGYS1PAICSDTWD1
CCDC59MAK16RUVBL2ISY1ECT2LGTPBP10
ZNF593RBM26FDXRMRI1HS1BP3LSM6
DNAJC8SALL4AATFLETM1LAS1LMRPS11
SMARCA5TMPOLTA4HMYCBPMRPL19NEPRO
PCBP2WBSCR22CCNHDLGAP5NDUFS7NOP58
HDAC2WDR48GLTSCR2PELP1HARS2NT5DC1
HIST1H1BTOX4TPI1LUC7LATP11CNXF1
HNRNPCVRK1KDM2ACOMMD8CACNA2D1RAD21
HNRNPUWIPI1USP39SSBCDCA7LSNF8
LARSASH2LVPS36ZNF346CRNKL1TELO2
LRRC57AASDHPPTCNPY3GLULCWC27TNPO3
CHORDC1CKAP2CXADRILF2PEG10TTI2
MANBADCAF13PLS1LVRNC1QBPUBE2A
MEMO1EIF4A3EXTL2MED24GLYR1UBXN1
MRPS18AEIF5BNIFKPOLR2HHMOX2ABCB6
NDUFB4FNBP1LNOL10KIF5CEXOSC9ATP2B1
TOMM40RBM28GSTP1TATDN1FTSJ3DAGLB
PLCG1IFI16HSPA4TMEM192MPISMPD4
POLE4KDM1ANUP188TSFMDLATFAM210A
POLR2DNOL6PRPF40AUBAP2MSTO1GTF2I
SHPKNUP133RBM12BDAB2IPSAFBLARP1
SPCS1PDHA1STX18PPFIA1NUP50METTL13
SAAL1QTRTD1SUPT6HADSLQSER1POLR3C
TRMT1LASUNBMP1AFG3L2GEMIN5NEU1
PEX6HDAC3NDC80MRRFHMGN1TIMM44
REEP6OTX2LPCAT1MTPAPSNU13UMPS
TRIAP1TUT1GRSF1NAA20ACSS3NCK1
ERBB2CCDC28BXRN2NDUFAF4MIFPPP2R5A
SGSHCRADDMT-ND4GATAD2AMRPL9RAD50
OSGEPL1ADGRL2MTUS2NRBF2FAM192ADNPEP
THAP11HEATR5BRABGEF1POP1HEATR3SRRM2
CACTINPRKD1MRPL50PRMT1NIPBLSTK4
SLC25A35ECE2RPL13ASDCBPNTMT1TBRG4
ZFAND6DSELSDAD1RPL21PDCD5PPIG
RALGAPBMYO5CTRMT6RBM39GULP1DCP1A
IGSF1POLGUBE3ASLC30A1RFC4TUBAL3
MGRN1TPK1KCTD10SMAPACIN1UBXN7
TMEM41ADNAL1F8A1,F8A2,F8A3TKFCBSGARHGEF40
FBP1FBXL6DFFBTRIM33EHBP1ATP5S
CDC20PLEKHA7WDR73CD70EMC3SLC9A3R1
COBLL1TRIM9SP1YARS2RBM19CKMT1A,CKMT1B
HSP90AB3PMRPL35CCNA2HDDC2KDM3BPPA1
SMARCAL1MALSU1AURKBPPM1GEARS2HSP90AA1
SH3GL3MPHOSPH6NACC2HMGB2GTPBP4ABCB10
CYP2U1BSDC1TLK1LEO1MFAP1GIT1
FLCNTYRO3SH3PXD2AEMC4CPS1INTS9
IRS2SIRT3FUT8CDK2TNFAIP6SDHAF4
KITLGALDH3A1GPR180CFAP36ANK3CBX2
RBBP9EML2POLR3GLFN3KVWA5ARAVER2
ATXN7L3BTIMM21SLC2A3CA14CRLF3SYT6
TMEM161AMTM1METTL15NKAPCDS2MRS2
MARS2ERCC2TDP1MFAP4ANAPC16CARS2
NOLC1IGHMBP2MRPL34FECHPARP2ING1
ADNP2STEAP3AK6PDZD8EPB41L5PEX16
ZER1CKS1BGGPS1DBNDD1MIEF1FUCA1
ADSSL1POTEJTMEM209CCNL2TOP3AULK1
MGAFAM162AAMMECR1ISG20L2CEP78NOM1
PAPD4PROCRIFRD2LRRC41UBR3PHF3
RIN1SPPL2BARAFDNM2HPS5PSEN1
PARD3ARHGEF16RHPN2PRPF18SEMA4CRPUSD3
NYNRINARHGEF7VRTNPHF10DMDRPL26L1
RANBP6CNOT4TSPYL5CDC25CREEP4FADD
INPP5FZBTB7AGPN3RBPMS2BRAFORC6
CACNA2D2AP1B1NCAPD3RRP8MASTLPOLR2M
CASC3NCLC1orf174LRRC14SLC27A3ACSF3
DHRS11RBM23WDR55CAMK4NDRG3ALS2
NOVA1SOX3CLCN7EHMT1C7orf26NSUN5
NMRAL1STK25NFKB2OSBPL1AVPS37BRAD23A
HS2ST1LYARPHKA1SDC4MGST2SNTB1
MEN1WDR4DDX28C1orf198AKAP9COQ9
STYXPHF5APCDH1TMSB4XAP1G2MYO1G
UCKL1APCTBC1D15FASTKD1APCDD1LMARH5
ULK3LONP2SETD1AETFDHANKS1ALRP8
PALD1ANAPC5CARMIL1GATMPANX1NME3
UBA52ZNF806NCOR2DVL2CTDP1PHKB
GINS3DNPH1CDCA5BCKDKTTF1TGFBRAP1
HAUS2HMGCRSNCAKLHDC4TBPAP1M2
E2F4AFAP1L1ZMYM6NBN4BP2TRIT1CCDC134
ATL1INTS6CHD8SPINT2RASA2NCK2
MAL2ATAD3ASLC25A32LSAMPACOT8KIFAP3
JARID2CLSTN1USP36PTGISPIAS4TMEM41B
SEC14L1TUBGCP4GEMIN8VWA9RPP25LNRBP2
DOLPP1WARS2PLEKHA6MRGBPZCCHC6ZFP36L1
SLC4A7SCARB1ARID1BPMF1XXYLT1ANKRD50
MT-CO1METRBM47LIN28BEXD2GORAB
GCSHPLTPPRKAB1CUTCSDSLFARS2
LRRC8EARHGAP12FBXW9PMS2NAA30STRA13
FASTKD5ZCCHC10TTKBNC2COX16BCS1L
NDE1STX3LARP1BPTCD1TPD52SMG1
ACBD7TRIP12PTPMT1ASB3MTG1ANKRD12
STK33HEXIM1RBM45ATG9AANKIB1B3GALNT2
C12orf43SLC25A15NDUFAF5BAG4NOA1SFRP2
VPRBPFOXK1GPM6BPOLETRADDAMFR
RPS6KA1PLA2G4ASELOPROM1CHTF18BOD1
SPC24KAT7RAB17IGFBP6PNPLA4AGTRAP
UBE2Q1HIGD2ARAPH1SDF2ARHGAP4ODR4
MRPS18CQSOX1COX17CHUKRAPGEF2GINS1
DFFACENPVPTPN9FUT11ERMP1SOGA1
DHX32GEMIN6HDHD2GLE1PTPRZ1CREG1
GATCPDXPMID1WRAP53POU2F1CA2
APPL1TMEM14CTXNIPSLC7A3FABP6ITGA2
CWC22MPDZPIGGACTBINCENPCARNMT1
RHBDD2MRPL38PUM1HPDLNME4CDKN2A
TRIM27ARHGEF10LBDH1CDC26CTU1ATF7
HMGXB4L3MBTL3MAP1LC3AISLRURB1MRPL21
CAMK1RILPL1WDR37IGF2BP1NAPEPLDDPH6
FCF1ANKRD29ANAPC13CD3EAPWDR89SLC25A17
DNA2CENPMCEP170BGCACSTF2TNKRF
SLC35A2PMS1SLC5A6COQ5SPRRBM15B
USP19LAMA4DNM1LINTS2BCAS3KIF22
NHEJ1RPP40TNCSPNS1RPRD1ADDB2
IFIT5ARMCX1FAT1DAPBMPR1ANPHP3
ARID3AMRPL13ZBED1GTF2H1PATZ1DPH2
C11orf98RRP7AAKAP1ANAPC1NUDT16CD74
DCAKDASB6DNMBPUTP11LTUBG1HAUS7
GAAPDK1DOHHISYNA1BRMS1EXOC6
ARAP3CHKBNOL8DDX52ORC5COA7
NAA40IQSEC1TRIM24DNTTIP1HEATR6SH3BP4
ZMYM3MED30CLASP2PRPF38BTMEM256GTF3C2
MRPL10NDUFAF7VCPIP1HSPB11CASP7TOR1B
ITPR2PRPF39GCFC2KIF21ADPPA4TIMM8B
GTF2H4MRPL16BAZ1AEXOC6BMRPL41POLR3B
USP9YSYNE2MID1IP1MOCS2METTL5PRUNE
UBE2V2CDH1GJA1CHMP6RCC1RAPGEF6
COMMD9HMBSSQLEIGFBP2DIAPH2EPB41
HIST1H1EMAP3K4CDK18ARL15UQCC1HTATIP2
PTDSS2TATDN2MTA1SNX18EIF1BMAEA
SCAF1UBE2J2NUP37BAG1TSSC4RCOR2
FAM213AMFFTTLL12UBXN6EFEMP2ZZEF1
NFYBPDS5BFXNAGPAT5ARFGEF2TCOF1
SCAF11RAPGEF1PARGPRIM1USF1L1TD1
SEPHS1BRD8POP7EXT2TSEN34CAMKV
SLC29A1MBD3PPIFMTX3COG1FASTKD2
ARL14EPMRPL40CD320MBD1VARS2BRD3
MRPS18BACY1PPIERIF1VPS8POGZ
RSL1D1PAK1STRBPTERF2TOP2ASLC39A10
QRICH1CISD1POLBDHX37TRMT5TIMMDC1
TRABDSONSETLYSTRNASEH2BMVK
ZC3HC1NDUFC1HSPA4LEXOSC1TCEANC2NASP
CYP2S1NSMCE3HPRT1HUS1PRRC2ARDH13
KANK1PHF14RBM7SIRT5QPCTLCROCC
LIMK2CWF19L1KIF1BVPS39CHD7YPEL5
SLC7A5VPS25LRWD1FPGSNT5C3ANCKIPSD
PSIP1CELF2MDC1ANP32AACADSBGPC4
TUBB4ABOP1NT5CCTSCANKLE2ORC4
UTP18CHST14NUS1PLK1GPKOWSIKE1
ADAM15NUDCD2SSU72NFYCLIG1MSH2
HNRNPRMSI2STK26EBPITPK1STAU2
URI1SLC7A8MANBALRNGTTPRIM2SEC24B
MRPS34RMND5AF11RSCAF8RPAP1SPATA5L1
RCC2POLRMTSERF2TMEM115PARP1C2CD5
BEND3BRAT1TERF2IPMT-ND2FAM136ANOP2
ARL5BGFM2WDR3AARSD1PPIDHRSP12
CHD2MRPL45YTHDF1THEMISINTS4PLEKHA1
CBX3SIRT7CENPFCAMSAP2MCCPTPN2
NANOGSLBPMCATMRPL24MZT1ANAPC4
HIST1H1AKPNA2MED14NDUFB9NEFLDUS3L
HSP90AA4PCMSS1ZNF706PTRHD1PBRM1ABI3BP
MED10PFASBRIX1QRSL1THNSL1ADRM1
CECR2NCOA5ABRACLWIPF2USP28GEMIN4
CHD1SBNO1LSM12COG2TARS2KIF11
CHD1LMLH1MNAT1DDX47SRPK1NACAP1
XPCNELFCDMPP6HAUS6TANC1PPAN
MRPL33PUM2MRPL15FAM65AERI3TOM1L2
TIMM13SPRYD4MICU1HMGN5XPO4WDR43
DDX20YTHDC2SLC25A22CACUL1PCF11PRC1
DNAAF2ACAT1RWDD4DHPSPFKMNUDT16L1
MTMR2GPN1SMARCA4EI24SCFD2PPP3CB
RNASEH2AGTF2E2SMARCD1ADCK3TRMT1RABEP1
CD97GLT8D1UBR5HLTFTXNRD2TDP2
CCNYNCAPD2USP48LRCH2UBQLN1TRIP10
MCM3HSPA14ZBTB8OSMAP2K7APOBEC3CTTC27
DYSFMINABAK1HERC2POLG2TRAP1
EXOSC7RCL1C17orf62PUS7CASP6ISOC1
THYN1MYL6CBR4RFC3SRSF10LCLAT1
HIBADHUHRF1DHX57MCM6UBL4AMRPS17
TFRCGALK2MKI67CEBPZCHRAC1TTC4
METTL3GSTZ1UBE2OLRSAM1NSA2AGPAT4
MRPS5MAP3K7ZNF330MLLT11HK2BLMH
PCCALYPLAL1CPSF2PEX3INPP4ASORD
SLC35F2MRPL23GNL3WBP11SAP30INPPL1
TBC1D9BMRPS31GMPSIMPDH2SSRP1LBR
TRIM28NELFBLDAHDDX21TWSG1RBMX
NDUFAF1PHF6TFB2MEBNA1BP2ZMYM2MLYCD
URODPKP3NUBP2FANCIARIH2ZNF22
USP11ARFRP1PKN1FAR1MYBBP1APDS5A
CHMP7COASYSAP18GTF3C4SMARCAD1DNAAF5
CTAGE5GARTUBE2IMRPL27ENY2PDK3
RUVBL1PEAK1WDR6MYEF2PWP2RPA2
EXOSC4FRA10AC1ADAD2NARS2FAM64AXRCC4
GTF2E1DDX51BMS1OGFRMRPL3CHAC2
PES1IGF2BP3LDHBORC3MSH6DPYSL5
HEATR1KATNA1PTMASLC52A2NLE1MCM7
POLD1MCM2CXorf56SMAD5GPATCH4STOML2
FLVCR1MYH14DAXXZCCHC8TAMM41TOMM34
LGALS3BPPARNKIF1BPC5orf22TP53RKNACC1
MRPS30TKTELAC2PRKCIPDCD11DNAJB4
MTMR12SUPV3L1DARS2RAVER1SIGMAR1DHODH
SLC3A2BTAF1HSDL1EIF3CTBPL1NOC2L
MRPS28CADM1MRPL37SRIBZW2NDUFC2
PCCBDNTTIP2PCBD2TRIM2CPSF1RABGGTB
RFC5ECT2AGTPBP1TRIM22ECM29PANK4
C11orf73MCAMTHUMPD1WDR18RNPS1SCO1
TIMM17BINTS8TUSC3DCAF16GTF2A1SIRT1
UTP6MRPL11XRN1DCTPP1HSPBP1TUFM
WDR92PIRACAA2DNAJC2NPM3ADNP
CERS6NUDT12APTXDSG2NTHL1BOLA3
DDX24NUP35ATL2NOL11DDX31ATPAF1
GCDHRCHY1C12orf10HIP1RPRPS2MCM5
WDR75RHOT1KIAA1211DDX54RSPRY1CDC123
NOP16TACO1GLMNHOOK1WNK1NUP155
POLR1ATBL3GNAI1KIAA2013C7orf50GUSB
GUF1TIMM17AGRWD1LBHCCNKILKAP
SMYD5AGLPORLIG3CMTR1LRBA
WDR5TOMM5ARL8APCK2PDCD4NAT10
ACO1TSC2GNL3LMTFP1ABT1KEAP1
ANKRD28UBTFSTK3SCAPPPATPSAT1
APOA1BPWDR54SYT1SCRIBPTBP3RNASEH2C
APOOASF1AGSPT2SDHBSUPT16HDBR1
PSME3PPWD1UBQLN4CHAF1ATRMT10CSACS
BYSLCDH13USP24ARID1AGJB2TEX10
UBA2CLUHARL2AS3MTABCC1MRPL57
DDX56EIF2DATP1B3DCAF8AGKAIF1L
RBM42FEN1CCDC12ELOVL6EFNB1NCAPG2
SARS2OSBPL2CDCA8GNA13ATF7IPCCDC50
ADI1HAUS8C1orf131GOLM1DEKDTD1
MCL1INTS1AHCYGYS1PAICSDTWD1
CCDC59MAK16RUVBL2ISY1ECT2LGTPBP10
ZNF593RBM26FDXRMRI1HS1BP3LSM6
DNAJC8SALL4AATFLETM1LAS1LMRPS11
SMARCA5TMPOLTA4HMYCBPMRPL19NEPRO
PCBP2WBSCR22CCNHDLGAP5NDUFS7NOP58
HDAC2WDR48GLTSCR2PELP1HARS2NT5DC1
HIST1H1BTOX4TPI1LUC7LATP11CNXF1
HNRNPCVRK1KDM2ACOMMD8CACNA2D1RAD21
HNRNPUWIPI1USP39SSBCDCA7LSNF8
LARSASH2LVPS36ZNF346CRNKL1TELO2
LRRC57AASDHPPTCNPY3GLULCWC27TNPO3
CHORDC1CKAP2CXADRILF2PEG10TTI2
MANBADCAF13PLS1LVRNC1QBPUBE2A
MEMO1EIF4A3EXTL2MED24GLYR1UBXN1
MRPS18AEIF5BNIFKPOLR2HHMOX2ABCB6
NDUFB4FNBP1LNOL10KIF5CEXOSC9ATP2B1
TOMM40RBM28GSTP1TATDN1FTSJ3DAGLB
PLCG1IFI16HSPA4TMEM192MPISMPD4
POLE4KDM1ANUP188TSFMDLATFAM210A
POLR2DNOL6PRPF40AUBAP2MSTO1GTF2I
SHPKNUP133RBM12BDAB2IPSAFBLARP1
SPCS1PDHA1STX18PPFIA1NUP50METTL13
SAAL1QTRTD1SUPT6HADSLQSER1POLR3C
TRMT1LASUNBMP1AFG3L2GEMIN5NEU1
PEX6HDAC3NDC80MRRFHMGN1TIMM44
REEP6OTX2LPCAT1MTPAPSNU13UMPS
TRIAP1TUT1GRSF1NAA20ACSS3NCK1
ERBB2CCDC28BXRN2NDUFAF4MIFPPP2R5A
SGSHCRADDMT-ND4GATAD2AMRPL9RAD50
OSGEPL1ADGRL2MTUS2NRBF2FAM192ADNPEP
THAP11HEATR5BRABGEF1POP1HEATR3SRRM2
CACTINPRKD1MRPL50PRMT1NIPBLSTK4
SLC25A35ECE2RPL13ASDCBPNTMT1TBRG4
ZFAND6DSELSDAD1RPL21PDCD5PPIG
RALGAPBMYO5CTRMT6RBM39GULP1DCP1A
IGSF1POLGUBE3ASLC30A1RFC4TUBAL3
MGRN1TPK1KCTD10SMAPACIN1UBXN7
TMEM41ADNAL1F8A1,F8A2,F8A3TKFCBSGARHGEF40
FBP1FBXL6DFFBTRIM33EHBP1ATP5S
CDC20PLEKHA7WDR73CD70EMC3SLC9A3R1
COBLL1TRIM9SP1YARS2RBM19CKMT1A,CKMT1B
HSP90AB3PMRPL35CCNA2HDDC2KDM3BPPA1
SMARCAL1MALSU1AURKBPPM1GEARS2HSP90AA1
SH3GL3MPHOSPH6NACC2HMGB2GTPBP4ABCB10
CYP2U1BSDC1TLK1LEO1MFAP1GIT1
FLCNTYRO3SH3PXD2AEMC4CPS1INTS9
IRS2SIRT3FUT8CDK2TNFAIP6SDHAF4
KITLGALDH3A1GPR180CFAP36ANK3CBX2
RBBP9EML2POLR3GLFN3KVWA5ARAVER2

Four groups are described: (i) proteins whose peptide counts increased more than two-fold in c-MYC-WT/HDFs compared with MYCL-WT/HDFs using SeV on day 3, 5, or 7; (ii) proteins whose peptide counts increased more than two-fold in c-MYC-WT compared with MYCL-WT using EpiP; (iii) proteins whose peptide counts increased more than two-fold in c-MYC-WT compared with c-MYC-ΔMB0 using EpiP; and (iv) commonly identified proteins. n=3 for EpiP reprogramming.

Table 3

MS analysis of identified proteins in cells reprogrammed with MYCL-WT and c-MYC-ΔMB0 compared with MYCL-ΔMB0.

(i) Proteins enriched more than two-fold in MYCL-WT compared with MYCL-ΔMB0 (EpiP)
UBQLN2DYNLRB1EXOC2KRT17NANSARL1
REEP5RAB11BARPC2TPM1UTP15TMPO
SGCDWDR46CD47SLC44A2RASA1CETN2
TUBB2AALDH6A1STRN3FBXW10BAP18SNW1
HMGB1POTEFPDHA1CAMK2DTM9SF3NFS1
PPICCOMMD4SCP2MT-ATP6YIPF5MPI
HMGB3TUSC3COL3A1ARF4ATP5PBMPDU1
PCNPMYD88GNB2NUCKS1LIMS1USP15
SYAP1RAC1COG6TMED2LRBAOVCA2
CHMP4BMACF1SOX2PRKACAMAPK14CALD1
UTP3SRSF11SSR1MID1DUSP12GBP1
BLOC1S1EXOC5CSTF3PCID2THOC3ANP32B
ST6GALNAC1DNAJC9CACNA2D1TRIP12SRSF5USP48
MAP3K20MICAL1NRDCGADD45GIP1VAC14PDIA4
KNTC1POLR2LMSRB3GTF2IPDXDC1SF3A3
BAG5SFXN3NOL11ERLIN2ZNF462NUCB2
CD320CRIP1OSTCDBNLITGB1AGK
MRPL11NAA10RPL37ASTT3ACTTNPPIL3
TFGARF6LZICPAFAH1B1EEF1B2IDI1
THYN1CCDC43BMP1SLC25A24UGP2ELN
NDRG3NEK7PDCL3HOOK3LSM2COL4A2
TMX4TUBB4BUGP2LAS1LACTBBUD31
SEPHS1MYO1ETNS3HLA-HRABL3MAP2
RPL36AFNTAVPS26BDCNRWDD1PAIP1
MYDGFSRBD1EHD1PUM1TOMM20ITGA5
OPTNDBIANKFY1PUS7CRABP2GPX8
GNAQSUGP2KBTBD3KPNA4VDAC3TXLNG
ACSL4MTA1SCPEP1METTL26EDIL3ATP5MG
ATP5MEMAP7D1FBLN2B4GALT4PLA2G4APIK3R4
ABI3BPACTG1LDLRMBD5CTNNA1PLBD2
ASAH1HINT1EXOSC7CSRP1RPL23AZYX
GNSHMGN1DIP2BGNB1TMEM165COX7C
WDR61PTGR1PITRM1SNRPB2DNAH6H3-3A,H3-3B
ARL8ATMSB4XMETTL14CNN2DPP9NCKAP1
MAP3K20FAM114A1TMSB10PPIBENDOD1AHNAK
NDRG1FTH1CNPY3S100A10NDUFB11PGM2
PITPNASGTAHABP2C1orf198NAA50PODXL
NIF3L1SGPL1SRP9MARCKSL1DNAJC8CFL2
NME2CD59NDUFB9TOR1AIP1NXNSTAT6
PFDN1DHRS4RBPJNDUFA4MRPS17TP53BP1
ATG3GSPT1DCTN5ACSS2REXO2ATAD1
ACIN1BLOC1S3TMED1GSTK1PEBP1EIF3K
RAB14RFC3AKR1B1ISLRS100A13GPX7
SNAP23CD55TALDO1NOP14SLC25A6TRIO
EMC2RPS15ADSTNPOLR2AOSBPL3TSPYL5

Three groups are described: (i) proteins whose peptide counts increased more than two-fold in MYCL-WT compared to MYCL-ΔMB0; (ii) proteins whose peptide counts increased more than two-fold in c-MYC-ΔMB0 compared to MYCL-ΔMB0; and (iii) commonly identified proteins. n = 3.

MYCL regulates cytoskeleton- and cell adhesion-related proteins during reprogramming via the MB0 domain. (A) Schematic of the mass spectrometry (MS) and GO analysis (DAVID). (B) Venn diagram of upregulated proteins during iPSC-like colony formation. (C) Molecular functions from the GO analysis of the four groups in (B). (D) KEGG pathways from the GO analysis of the four groups in (B). MS analysis of identified proteins in cells reprogrammed by MYCL- or c-MYC-ΔMB0. Four groups are described: (i) proteins whose peptide counts increased more than two-fold in MYCL-WT/HDFs compared with c-MYC-WT/HDFs using SeV on day 3, 5, or 7; (ii) proteins whose peptide counts increased more than two-fold in MYCL-WT compared with c-MYC-WT using EpiP; (iii) proteins whose peptide counts increased more than two-fold in c-MYC-ΔMB0 compared with c-MYC-WT using EpiP; and (iv) commonly identified proteins. Bold fonts in the group (ii) indicate identified proteins with p < 0.05 (two-sample paired t-test). n = 3 for EpiP reprogramming. MS analysis of identified proteins in cells reprogrammed with c-MYC. Four groups are described: (i) proteins whose peptide counts increased more than two-fold in c-MYC-WT/HDFs compared with MYCL-WT/HDFs using SeV on day 3, 5, or 7; (ii) proteins whose peptide counts increased more than two-fold in c-MYC-WT compared with MYCL-WT using EpiP; (iii) proteins whose peptide counts increased more than two-fold in c-MYC-WT compared with c-MYC-ΔMB0 using EpiP; and (iv) commonly identified proteins. n=3 for EpiP reprogramming. MS analysis of identified proteins in cells reprogrammed with MYCL-WT and c-MYC-ΔMB0 compared with MYCL-ΔMB0. Three groups are described: (i) proteins whose peptide counts increased more than two-fold in MYCL-WT compared to MYCL-ΔMB0; (ii) proteins whose peptide counts increased more than two-fold in c-MYC-ΔMB0 compared to MYCL-ΔMB0; and (iii) commonly identified proteins. n = 3. We also compared phosphorylated proteins during SeV reprogramming with MYCL and c-MYC. In total, there was more than a two-fold relative increase of 17 phosphorylated proteins with MYCL-WT and 132 phosphorylated proteins with c-MYC-WT. The GO analysis indicated that the phosphorylated proteins increased by MYCL included cytoskeleton-related proteins and those increased by c-MYC included transcription-related proteins (Supplementary Fig. S11).

MYCL regulates RNA processing-related proteins during reprogramming via the MB2 domain

Our analysis also revealed that, along with the MYCL MB0 domain, the MYCL MB2 domain is important for reprogramming (Fig. 2B). It has been reported that the c-MYC MB2 domain is involved in transformation activity, and tryptophan 135 within the MB2 domain is necessary for this activity[10]. MYCL also has a tryptophan residue within its MB2 domain but little transformation activity[23]. We hypothesized that this domain in MYCL has reprogramming function. We therefore produced a mutant in which tryptophan 96 was substituted with glutamate (W96E). This tryptophan is equivalent to tryptophan 135 in c-MYC (Fig. 4A and Supplementary Fig. S5B). We confirmed the expression of MYCL-W96E by western blotting (Supplementary Fig. S12). Next, we examined the effect of MYCL-W96E for reprogramming. HDFs were transfected with reprogramming factors including MYCL-WT or -W96E. MYCL-W96E could not induce iPSC-like colonies, suggesting tryptophan 96 is crucial for reprogramming (Fig. 4B, C). We thus hypothesized that the residue might be important for MYCL to bind to other proteins. To identify the binding proteins, we produced GST-fusion recombinant proteins of the MYCL MB2 domain (Fig. 4A). GST-MYCL-MB2-WT or -W96E proteins were immobilized on glutathione Sepharose, and affinity columns were prepared. Cell lysates were applied to the column, and, after washing, the bound proteins were eluted. We used the cell lysates from reprogramming HDFs, but since it was difficult to collect a large amount, we also used cell lysates from hiPSCs. The reason for using the hiPSC lysates is that many of the proteins expressed in reprogramming HDFs are highly expressed in hiPSCs as well[16,24-27].
Figure 4

MYCL regulates RNA processing-related proteins during reprogramming via the MB2 domain. (A) W96 and W135 in the MB2 domain of MYCL and c-MYC, respectively. The structure with the recombinant protein of the MB2 domain of MYCL-WT/W96E is shown below. The numbers on the right indicate amino acid lengths. (B) The number of iPSC-like and non-iPSC-like colonies derived from 1 × 105 HDFs transduced with EpiP including MYCL-WT or MYCL-W96E on day 21. Mean ± SD values are shown. n = 3, *p < 0.05 by unpaired t-test. (C) Representative images of reprogramming HDFs 21 days after the transduction of EpiP, including MYCL-WT or MYCL-W96E. Scale bars, 100 μm. (D) Venn diagram of enriched proteins between reprogramming HDFs and hiPSCs by AP-MS. A list of the 25 commonly enriched proteins is shown below. Blue indicates RBP (23 in total). (E) Molecular function from the GO analysis of the 25 commonly identified proteins in (D).

MYCL regulates RNA processing-related proteins during reprogramming via the MB2 domain. (A) W96 and W135 in the MB2 domain of MYCL and c-MYC, respectively. The structure with the recombinant protein of the MB2 domain of MYCL-WT/W96E is shown below. The numbers on the right indicate amino acid lengths. (B) The number of iPSC-like and non-iPSC-like colonies derived from 1 × 105 HDFs transduced with EpiP including MYCL-WT or MYCL-W96E on day 21. Mean ± SD values are shown. n = 3, *p < 0.05 by unpaired t-test. (C) Representative images of reprogramming HDFs 21 days after the transduction of EpiP, including MYCL-WT or MYCL-W96E. Scale bars, 100 μm. (D) Venn diagram of enriched proteins between reprogramming HDFs and hiPSCs by AP-MS. A list of the 25 commonly enriched proteins is shown below. Blue indicates RBP (23 in total). (E) Molecular function from the GO analysis of the 25 commonly identified proteins in (D). We identified 31 candidate proteins that bind to the MB2 domain of MYCL-WT but not of MYCL-W96E during reprogramming in the HDF lysates (Fig. 4D and Table 4). Of those 31 proteins, 25 proteins were also identified using hiPSC lysates, and 23 were RNA-binding proteins (RBPs; Fig. 4D, genes written in blue). Six proteins were identified only in the reprogramming HDFs lysates: HNRNPK, DDX17, C1QBP, KBTBD3, COPG2, and SIKE1, of which HNRNPK, DDX17, and C1QBP are RBPs. From these results, there were 26 RBPs identified in the HDF lysates in total. We confirmed the function of the 31 proteins using a public database (https://www.nextprot.org/)[28] and found 16 of them are involved in RNA processing. A GO analysis using DAVID also showed that the 31 proteins are related to controlling pre-mRNA splicing, capping, and polyadenylation, suggesting functions in mRNA export, turnover, localization, and translation (Fig. 4E). These results suggested that MYCL interacts with RBPs via its MB2 domain and promotes reprogramming by post-transcriptional regulation.
Table 4

AP-MS analysis of identified proteins in MYCL-MB2-WT using cell lysates from reprogrammed HDFs and hiPSCs.

(i) Proteins enriched more than two-fold in MYCL-MB2-WT compared with MYCL-MB2-W96E (reprogramming HDFs) (31)
HNRNPA1HNRNPDHNRNPDLHNRNPA2B1HNRNPA0HNRNPA3
KHDRBS1HNRNPABALYREFDDX5HNRNPUSYNCRIP
HNRNPRHNRNPKDDX17C1QBPFAURPL22
RPL37ARPL23ANCLRPS24RPL31RPS4X
RPS7CIRBPMCFD2KBTBD3COPG2PTGES3
SIKE1
Italic valueRNA binding proteins
Bold italic value : RNA processing proteins

Three groups are described: (i) protein interactors whose peptide counts increased in reprogramming HDFs more than two-fold in MYCL-MB2-WT than MYCL-MB2-W96E; (ii) protein interactors whose peptide counts increased in hiPSCs more than two-fold in MYCL-MB2-WT compared to MYCL-MB2-W96E; and (iii) commonly identified proteins. n = 1.

AP-MS analysis of identified proteins in MYCL-MB2-WT using cell lysates from reprogrammed HDFs and hiPSCs. Three groups are described: (i) protein interactors whose peptide counts increased in reprogramming HDFs more than two-fold in MYCL-MB2-WT than MYCL-MB2-W96E; (ii) protein interactors whose peptide counts increased in hiPSCs more than two-fold in MYCL-MB2-WT compared to MYCL-MB2-W96E; and (iii) commonly identified proteins. n = 1.

Discussion

Here we described the molecular function of MYCL during reprogramming and compared it to the c-MYC function by focusing on MYC Box domains. We found that the MB0 and MB2 domains are important for reprogramming, and deleting either region compromised the reprogramming ability of MYCL. Proteomic analysis revealed that MYCL regulates the expression of cell adhesion-related proteins during reprogramming via the MB0 domain (Fig. 3C, D). We also found the possibility that the same domain is regulated by post-translational modifications (PTM), as discussed below. It is known that cell-substrate adhesion is closely related to the mesenchymal-epithelial transition (MET)[29] and that MET occurs during the reprogramming process[30-32]. We speculate that MYCL promotes iPSC-like colony formation via the MET process by upregulating cell adhesion-related genes. Furthermore, we identified that the MB2 domain is required for MYCL to promote reprogramming by binding to RBPs, especially RNA processing-related proteins (Fig. 4D, E). It has been reported that RBPs regulate MET through post-transcriptional regulation. For example, heterogeneous nuclear ribonucleoprotein (hnRNP) A1 regulates the alternative splicing of Rac1 to control MET[33]. These findings suggest that MYCL regulates the RNA processing of cell adhesion-related genes transcribed by MYCL itself or other genes. Therefore, we hypothesize that transcriptional and post-transcriptional regulation by MYCL promotes MET, which increases the efficiency of reprogramming and leads to higher quality iPSCs. Western blotting revealed that MYCL protein has a unique expression pattern (Supplementary Fig. S8 and S12). The calculated molecular weight of MYCL is about 40 kDa (364 aa), but we detected three strong bands at around 60 kDa, which we verified with second antibody (Supplementary Fig. S13). Since the expression of MYCL-ΔMB0 showed a strong single band, we speculate that the MYCL MB0 domain is the PTM site (Supplementary Fig. S8). Such a phenomenon was not observed in c-MYC (Supplementary Fig. S7). One possible type of relevant PTM is phosphorylation. Phosphorylation is crucial for protein function. For example, RNA polymerase II (Pol II) is required for transcription pauses in a promoter-proximal position during transcription initiation. In order to initiate transcription, the C-terminal domain of Pol II must be phosphorylated by P-TEFb[34]. In addition, the phosphorylation of c-MYC on threonine 58 in the MB1 domain promotes c-MYC binding to F-box and WD repeat domain containing 7 (FBXW7), causing the ubiquitination of c-MYC, which triggers c-MYC degradation[35]. Similarly, MYCL might undergo phosphorylation to change its activity and interaction with binding proteins. However, this hypothesis requires further study. Comprehensive proteomic analysis suggested that the MYCL MB0 domain influences the expression of cell adhesion-related proteins, and MYCL shows an up-regulation of phosphorylated cytoskeletal proteins (Fig. 3C, D, and Supplementary Fig. S11A). Cell adhesion is mediated by adhesion molecules, such as integrins and cadherins, which function in the extracellular matrix (ECM) and cell–cell adhesion and are important for cell communication and the regulation of fundamental physiological processes such as tissue development and maintenance[36,37]. Human iPSCs and hESCs have unique focal adhesion localization, and appropriate adhesion to the ECM is required to regulate reprogramming via MET and maintain pluripotency[38-40]. Accordingly, our study supports MYCL regulating cell-substrate adhesion through its MB0 domain to promote reprogramming. In other words, MYCL might regulate proteins involved in cell adhesion and the cytoskeleton directly or indirectly to cause MET and promote reprogramming. In c-MYC, loss of the MB0 domain positively affects iPSC-like colony formation, suggesting that this domain has a different function compared to MYCL. This functional difference is somewhat surprising since the domain is well conserved (Supplementary Fig. S5B). We would like to clarify this point in the future. We also found that the MB2 domain has an important function in MYCL-reprogramming (Fig. 2B,C). Deleting the MB2 domain completely compromised the reprogramming ability of MYCL. In c-MYC, the MB2 domain has an important function in transformation activity[14], and tryptophan 135 in the MB2 domain is essential for this activity. The equivalent tryptophan residue in MYCL is tryptophan 96. MYCL has little transformation activity, but we showed that the mutation of tryptophan 96 completely lost the reprogramming ability of MYCL. To further investigate the function, we sought interacting proteins by affinity column chromatography. We found 31 proteins, including 26 RBPs, that interact with the MYCL MB2 domain (Table 4, genes written in blue). A GO analysis suggested that some of the 31 proteins are involved in RNA processing (Table 4). It has been reported that altered RNA processing affects somatic cell reprogramming[41]. Therefore, we hypothesize that MYCL also promotes MET in reprogramming by regulating RNA processing via interactions with RBPs at its MB2 domain. An illustrative summary of how MYCL regulates cell reprogramming through these two domains is shown in Fig. 5.
Figure 5

Model of the reprogramming process by MYCL. MYCL promotes iPSC-like colonies via its MB0 and MB2 domains. The MB0 domain regulates the expression of cell-adhesion proteins, possibly via post-translational modifications (PTM). The MB2 domain regulates RNA processing by interacting with RNA-binding proteins (RBP). We speculate that MYCL promotes reprogramming through the synergistic effects of these two mechanisms.

Model of the reprogramming process by MYCL. MYCL promotes iPSC-like colonies via its MB0 and MB2 domains. The MB0 domain regulates the expression of cell-adhesion proteins, possibly via post-translational modifications (PTM). The MB2 domain regulates RNA processing by interacting with RNA-binding proteins (RBP). We speculate that MYCL promotes reprogramming through the synergistic effects of these two mechanisms. To conclude, we have demonstrated that MYCL promotes more efficient reprogramming than c-MYC, regulates the expression of cell adhesion and cytoskeletal proteins, and is involved in RNA processing via a single tryptophan residue in the MB2 domain. Following these findings, we propose that MYCL causes MET by regulating the expression of proteins involved in the promotion of reprogramming from the RNA-processing stage. Further elucidation of the function of MYCL in reprogramming will improve the quality and efficiency of iPSC generation.

Material and methods

Cell culture

HDFs (106-05f.) were purchased from Cell Applications, Inc. HDFs were cultured in DMEM (08459-64, Nacalai Tesque) supplemented with 10% FBS (10439-024, gibco) and 1% penicillin and streptomycin (15140-122, Pen/Strep, gibco). The hiPSC clone 201B7 was used in this study[2]. iPSCs were cultivated on iMatrix-511 (NP892-012, Nippi)-coated (0.5 μg/cm[2]) cell culture plates with StemFit (AK03N, Ajinomoto) supplemented with bFGF and passaged via dissociation into single cells using TrypLE Select (A12859-01, Life Technologies) on day 7 following a previously reported protocol[42].

Generation of iPSCs

A frozen stock of HDFs was thawed and cultured for four days, and then 1 × 105 cells were collected by trypsinization. With SeV, HDFs were transduced with the CytoTune-iPS 2.0 (c-MYC) or CytoTune-iPS 2.0L (MYCL) Sendai Reprogramming Kit (DV-0304, DV-0305, ID Pharma). With EpiP, HDFs were electroporated with 1.2 μg of plasmid mixtures with the Neon Transfection System (MPK1096 and MPK10096, Invitrogen). The plasmid mixtures included pCXLE-SOX2, -KLF4, -OCT3/4-shp53, -LIN28A, and pCXWB-EBNA1 with wild-type or mutant pCXLE-c-MYC or -MYCL[17]. The mixing ratio of SOX2, KLF4, OCT3/4-shp53, LIN28A, EBNA1, and c-MYC/MYCL was 1:1:2:1:0.5:2. After that, the cells were plated in a 6-well plate and cultured in StemFit AK03N without bFGF with iMatrix-511 at 0.25 μg/cm2 in SeV or 0.125 μg/cm2 in EpiP. The culture medium was changed the next day and every three days after that. The colonies were counted 21 days after plating.

Episomal plasmid vector construction for deletion mutants of c-MYC and MYCL

We previously generated pCXLE-c-MYC and -MYCL from human cDNAs encoding c-MYC and MYCL amplified by PCR and cloned into pENTR1A[17]. Primers for the deletion mutants were designed using the Primer Design tool for the In-Fusion HD Cloning Kit (639650, Takara) and inserted into pENTR1A. The switch from pENTR1A to pCXLE was done using the Gateway system (11791020, Invitrogen). The primers used are listed in Table S1.

Immunostaining

The cells were fixed with 4% formaldehyde (163-20145, Wako) for 20 min at room temperature. Then, the fixed cells were treated with PBS (14249-24, Nacalai Tesque) containing 0.5% Triton X-100 (35501-15, Nacalai Tesque) and 3% bovine serum albumin (01281-84, BSA, Nacalai Tesque) for 20 min at room temperature for permeabilization. The cells were incubated with primary antibodies diluted in PBS containing 3% BSA at 4℃ overnight. After washing with PBS, the cells were incubated with fluorescence-conjugated secondary antibodies for 1 h at room temperature. Nuclei were visualized with Hoechst 33342 (346-07951, DOJINDO). Anti-TRA-1-60 (1:500, 560071, BD Pharmingen, and 1:500, 09-0068, Stemgent) and Alexa 488-conjugated goat anti-mouse IgG, IgM (H + L) (1:250, A10680, Invitrogen) were used as the antibodies.

Imaging and quantification

Stained cells were imaged using a BZ-9000 imaging system (KEYENCE) or ArrayScan High-Content Systems (Thermo Fisher Scientific). HCS Studio 2.0 Cell Analysis Software (Thermo Fisher Scientific) was used to quantify cell counts and signal intensities. The Cellomics BioApplication system (Thermo Fisher Scientific) was programmed to capture and analyze 25 images per well. The total cell number was detected by Hoechst 33342 staining. The number of TRA-1-60 ( +) cells was calculated as the number of TRA-1-60 ( +) cells among Hoechst ( +) cells. TRA-1-60 ( +) cells were calculated by dividing this number by the total cell number.

Flow cytometry

Transduced cells were harvested with 0.25% trypsin/1 mM EDTA (25200-056, gibco) each day after the transduction for the analysis. At least 5 × 104 cells were stained with the following antibodies in FACS buffer (2% FBS, 0.36% glucose (16806-25, Nacalai Tesque), 50 μg/μL Pen/Strep in PBS) for 30 min at room temperature: BV510-conjugated anti-TRA-1-60 (1:40, 563188, BD Biosciences) and PE-Cy7-conjugated anti-CD13 (1:40, 561599, BD Biosciences) antibodies. The analysis was performed using MACSQuant Analyzers (Miltenyi Biotec). Negative controls used a mixture of HDFs without any EpiP transduction and reprogramming HDFs electroporated with EpiP including c-MYC or MYCL. “Isotype” means mixed HDFs stained with the isotype control of anti-TRA-1-60 (1:40, 563082, BD Biosciences) and -CD13 (1:40, 557646, BD Biosciences) antibodies.

SDS-PAGE

Cells were lysed with SDS sample buffer (0.125 M Tris-base (35434-21, Nacalai Tesque), 0.96 M glycine (17109-35, Nacalai Tesque), and 17.3 mM SDS (31606-75, Nacalai Tesque)) containing 3-mercaptoethanol (139-16452, Wako). Samples were applied and separated in an 8% polyacrylamide gel composed of 30% (w/v)-Acrylamide/Bis Mixed Solution (29:1) (06141-35, Nacalai Tesque), Separating Gel Buffer Solution (4x) (30651-05, Nacalai Tesque) and Stacking Gel Buffer Solution (4x) (32158-25, Nacalai Tesque) for SDS-PAGE.

Western blotting

Proteins on an SDS-PAGE gel were transferred to a PVDF membrane (IPVH00010, Immobilon-P, Millipore) and probed with the following antibodies using an iBind Flex system (SLF2000, SLF2010 and SLF2020, Invitrogen): anti-human MYCL (1:250, AF4050, R&D) (1:250, C-20, sc-790, Santa Cruz), anti-human c-MYC (1:500, 9E10, sc-40, Santa Cruz, and 1:500, D84C12, CST), anti-β-actin (1:1000, A5441, SIGMA), anti-Goat (1:3000, ab6741-1, abcam), anti-mouse (1:3000, 7076S, CST), and anti-rabbit (1:3000, 7074S, CST) antibodies.

Preparation of recombinant proteins and affinity purification (AP)

The MB2 region of MYCL-WT or -W96E was cloned into pGEX-6P-1. The plasmids were transformed into BL21 E. coli (DE3) (L1198, Promega) competent cells. The fusion proteins, GST-MYCL-WT-MB2 and GST-MYCL-W96E-MB2, were induced by treatment with 0.5 mM IPTG (19742-94, Nacalai Tesque) for 4 h at 37 °C. The proteins were purified using glutathione Sepharose beads (17-0756-01, GE Healthcare). Human iPSCs or reprogramming HDFs were lysed in RIPA buffer (20 mM Tris/HCl (pH 7.6) (35436-01, Nacalai Tesque), 1% NP-40 (25223-75, Nacalai Tesque), 0.1% SDS, 150 mM NaCl (31320-05, Nacalai Tesque), and protease inhibitor (25955-11, Nacalai Tesque)) and then centrifuged. Cell lysates (supernatant) were transferred into a column (29922, Thermo Fisher Scientific) packed with beads conjugated with GST- MYCL-WT or -W96E proteins. After washing, binding proteins were eluted in lysis buffer (12 mM sodium deoxycholate (190-08313, Wako), 12 mM sodium lauroyl sarcosinate (192-10382, Wako), and 100 mM Tris-HCl (pH9.0) (314-90381, NIPPON GENE)) for the MS analysis. The iPSC lysates were prepared 6 days after passaging in two 10-cm dishes (n = 1), and reprogramming HDF lysates were prepared 3 days after SeV transduction in five 10-cm dishes (n = 1).

GO analysis by DAVID

The Database for Annotation, Visualization, and Integrated Discovery (DAVID Bioinformatics Resources 6.8) was used to identify enriched biological GO terms and KEGG pathway[43-45]. For more information, please visit the DAVID website (https://david.ncifcrf.gov/home.jsp) and KEGG Database website (https://www.kegg.jp/kegg/kegg1.html). The methods for MS are described in the Supplementary methods. Supplementary Information 1. Supplementary Information 2. Supplementary Information 3.
  44 in total

1.  Regulation of RNA polymerase II elongation by c-Myc.

Authors:  David H Price
Journal:  Cell       Date:  2010-04-30       Impact factor: 41.582

Review 2.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

Review 3.  The molecular genetics of cellular oncogenes.

Authors:  H E Varmus
Journal:  Annu Rev Genet       Date:  1984       Impact factor: 16.830

4.  Promotion of direct reprogramming by transformation-deficient Myc.

Authors:  Masato Nakagawa; Nanako Takizawa; Megumi Narita; Tomoko Ichisaka; Shinya Yamanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

5.  Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency.

Authors:  Jenny Hansson; Mahmoud Reza Rafiee; Sonja Reiland; Jose M Polo; Julian Gehring; Satoshi Okawa; Wolfgang Huber; Konrad Hochedlinger; Jeroen Krijgsveld
Journal:  Cell Rep       Date:  2012-12-27       Impact factor: 9.423

6.  MB0 and MBI Are Independent and Distinct Transactivation Domains in MYC that Are Essential for Transformation.

Authors:  Qin Zhang; Kimberly West-Osterfield; Erick Spears; Zhaoliang Li; Alexander Panaccione; Stephen R Hann
Journal:  Genes (Basel)       Date:  2017-05-06       Impact factor: 4.096

Review 7.  Unchain My Heart: Integrins at the Basis of iPSC Cardiomyocyte Differentiation.

Authors:  Rosaria Santoro; Gianluca Lorenzo Perrucci; Aoife Gowran; Giulio Pompilio
Journal:  Stem Cells Int       Date:  2019-02-13       Impact factor: 5.443

8.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

9.  A Strong Contractile Actin Fence and Large Adhesions Direct Human Pluripotent Colony Morphology and Adhesion.

Authors:  Elisa Närvä; Aki Stubb; Camilo Guzmán; Matias Blomqvist; Diego Balboa; Martina Lerche; Markku Saari; Timo Otonkoski; Johanna Ivaska
Journal:  Stem Cell Reports       Date:  2017-06-15       Impact factor: 7.765

10.  KEGG: integrating viruses and cellular organisms.

Authors:  Minoru Kanehisa; Miho Furumichi; Yoko Sato; Mari Ishiguro-Watanabe; Mao Tanabe
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.